ECSP077649A - PIRIDAZINONILOS MACROCICLICOS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C - Google Patents

PIRIDAZINONILOS MACROCICLICOS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C

Info

Publication number
ECSP077649A
ECSP077649A EC2007007649A ECSP077649A ECSP077649A EC SP077649 A ECSP077649 A EC SP077649A EC 2007007649 A EC2007007649 A EC 2007007649A EC SP077649 A ECSP077649 A EC SP077649A EC SP077649 A ECSP077649 A EC SP077649A
Authority
EC
Ecuador
Prior art keywords
hepatitis
serine protease
compounds
piridazinonilos
macrociclicos
Prior art date
Application number
EC2007007649A
Other languages
Spanish (es)
Inventor
Or Yat Sun
Zhe Wang
Joel D Moore
Datong Tang
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/832,893 external-priority patent/US7718612B2/en
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of ECSP077649A publication Critical patent/ECSP077649A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Compuestos de Fórmula I, o sus sales aceptables para uso farmacéutico, ésteres o prodrogas, que inhiben la actividad de serina proteasa , particularmente la actividad de la NS3-NS4A proteasa del virus de hepatitis C (VHC). En consecuencia, los compuestos de la presente invención interfieren con el ciclo de vida del virus de hepatitis C y también son útiles como agentes antivirales. Composiciones farmacéuticas que comprenden dichos compuestos para su administración a un sujeto afectado por una infección por VHC. Métodos para tratar una infección por VHC en un sujeto administrando una composición farmacéutica que comprende un compuesto de la presente invención.Compounds of Formula I, or their salts acceptable for pharmaceutical use, esters or prodrugs, which inhibit the activity of serine protease, particularly the activity of the NS3-NS4A protease of hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Pharmaceutical compositions comprising said compounds for administration to a subject affected by an HCV infection. Methods for treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

EC2007007649A 2006-08-04 2007-08-06 PIRIDAZINONILOS MACROCICLICOS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C ECSP077649A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49984406A 2006-08-04 2006-08-04
US11/832,893 US7718612B2 (en) 2007-08-02 2007-08-02 Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors

Publications (1)

Publication Number Publication Date
ECSP077649A true ECSP077649A (en) 2008-03-26

Family

ID=39033583

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007649A ECSP077649A (en) 2006-08-04 2007-08-06 PIRIDAZINONILOS MACROCICLICOS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C

Country Status (4)

Country Link
CO (1) CO6020004A1 (en)
EC (1) ECSP077649A (en)
PE (1) PE20080539A1 (en)
WO (1) WO2008019303A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AR057456A1 (en) 2005-07-20 2007-12-05 Merck & Co Inc HCV PROTEASA NS3 INHIBITORS
UA93990C2 (en) 2005-10-11 2011-03-25 Интермюн, Инк. Compounds and methods for inhibiting hepatitis c viral replication
KR20090024834A (en) 2006-07-05 2009-03-09 인터뮨, 인크. Novel inhibitors of hepatitis c virus replication
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CA2763122A1 (en) * 2009-05-22 2010-11-25 Sequoia Pharmaceuticals Inc. Bimacrocyclic hcv ns3 protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
CN102843909A (en) 2010-01-25 2012-12-26 埃南塔制药公司 Hepatitis c virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2014506255A (en) 2010-12-30 2014-03-13 エナンタ ファーマシューティカルズ インコーポレイテッド Phenanthridine macrocyclic hepatitis C serine protease inhibitor
CN103534256B (en) 2010-12-30 2016-08-10 益安药业 Macrocyclic hepatitis c serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2613766T3 (en) 2012-10-19 2017-05-25 Bristol-Myers Squibb Company Carbamate derivatives of hexadecahydrocyclopropa (e) pyrrolo (1,2-a) (1,4) diazacyclopentadecinyl substituted with 9-methyl as inhibitors of non-structural protease 3 (NS3) for the treatment of hepatitis C virus infections
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
JP6342922B2 (en) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Hepatitis C virus inhibitor
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
EP1590442A4 (en) * 2003-02-07 2007-07-18 Enanta Pharm Inc Macrocyclic hepatitis c serine protease inhibitors

Also Published As

Publication number Publication date
WO2008019303A2 (en) 2008-02-14
WO2008019303A3 (en) 2008-10-30
PE20080539A1 (en) 2008-05-16
CO6020004A1 (en) 2009-03-31

Similar Documents

Publication Publication Date Title
DOP2019000218A (en) INHIBITORS OF MACROCYCLIC PROLINES DERIVED HCV SERINE PROTEASES
ECSP077648A (en) MACROCICLIC TETRAZOLILS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C
ECSP077649A (en) PIRIDAZINONILOS MACROCICLICOS AS INHIBITORS OF SERINE PROTEASE OF HEPATITIS C
AR061238A1 (en) HEPATITIS C PROTEASE INHIBITORS MACROCICLIC OXYLMYL COMPOUNDS
UY30391A1 (en) HEPATITIS C PROTEASE INHIBITORS ACICLIC OXYM COMPOUND
ECSP10010254A (en) COMPOUNDS CONTAINING QUINOXALINE AS INHIBITORS OF THE HEPATITIS C VIRUS
UY30437A1 (en) QUINOXALINIL MACROCECLIC INHIBITORS OF SERINE PROTEASE VIRUS OF HEPATITIS C
CO6571891A2 (en) Hepatitis C virus inhibitors
CO2020002980A2 (en) Antiviral agents against hepatitis b.
UY28423A1 (en) INHIBITORS OF SERINE PROTEASES, IN SPECIAL PROTEASA NS3-NS4A OF HCV.-
UY37997A (en) ANTIVIRAL AGENTS AGAINST HEPATITIS B
MX2010010276A (en) Fluorinated macrocyclic compounds as hepatitis c virus inhibitors.
DOP2013000238A (en) DERIVATIVES OF NUCLEOSIDS 2'-SUBSTITUTES AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIRAL DISEASES
ECSP088258A (en) SERINA PROTEASAS INHIBITORS
UY28500A1 (en) INHIBITORS OF SERINE PROTEASES, IN PARTICULAR PROTEASA NS3-NS4A HCV.
MX2010006210A (en) Fluorinated tripeptide hcv serine protease inhibitors.
MX2010006518A (en) Macrocyclic oximyl hepatitis c serine protease inhibitors.
MX2010008109A (en) Difluorinated tripeptides as hcv serine protease inhibitors.
MX2010008108A (en) Heteroaryl-containing tripeptide hcv serine protease inhibitors.
TH139657A (en) HCV serine protease inhibitors that provide macro-cyclic proline.